| Field | Specification |
|---|---|
| Target | |
| Alternative names | Cadherin-13; Heart cadherin; H-cadherin; P105; Truncated cadherin; T-cad; T-cadherin; CDH13; CDHH |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human H Cadherin/CDH13 recombinant protein (Position: E149-A692). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets cadherin-13 (gene CDH13) in human and rat samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 78.3 kDa; the supplier reports observed bands at 105 kDa, 130 kDa.
Cadherin-13 (CDH13), also called T-cadherin or H-cadherin, is an atypical cadherin that lacks transmembrane and cytoplasmic domains and is attached to the membrane by a GPI anchor. It acts as a receptor for adiponectin and LDL and regulates neural and vascular cell growth, making it relevant to cardiovascular and neurodevelopmental research.
| Target | Cadherin-13 (gene CDH13; UniProt P55290, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 78.3 kDa |
| Observed MW | 105 kDa, 130 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 1–2 µg/mL (Human, Rat) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human U87 cells, human HeLa cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human appendicitis tissue, human gastric cancer tissue, human renal carcinoma tissue, human melanoma tissue, human ovarian cancer tissue, human skeletal muscles tissue, human skin cancer tissue, rat cardiac muscle tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): SIHA cells.
Samples with a confirmed signal (flow cytometry): HeLa cells.
Immunogen
Recombinant human H Cadherin/CDH13 fragment (Glu149–Ala692), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human and rat. UniProt places cadherin-13 in the cell membrane and cytoplasm. Tissue expression noted by UniProt (human): Highly expressed in heart. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
